Juvenon Initiates Cardiovascular Disease Clinical Trial
Orinda CA, 6 May 2003

Juvenon Energy Formula™ Designed to Improve Energy Levels and Reduce Signs of Aging

Juvenon, Inc. today announced the initiation of a clinical trial to evaluate the effect of Juvenon Energy Formula™ on cardiovascular disease patients. The trial, funded by a grant from the National Institutes of Health (NIH), is being conducted at the Whitaker Cardiovascular Institute, a unit of Boston University School of Medicine. It is designed to assess the effects of Juvenon Energy Formula on endothelial function in elderly patients with coronary artery disease. Dysfunction of the endothelial cells, the cells that line the blood vessels, contributes to the progression of cardiovascular disease and is recognized as an important surrogate for cardiovascular disease risk.

"Juvenon Energy Formula has been shown in preclinical trials to reduce oxidative damage to the mitochondria, thereby improving cellular function," said Joseph Vita, MD, Professor of Medicine, Boston University Medical Center, and principal investigator. "Recent research indicates that oxidative damage to the cells in the vascular system contributes to the risk of heart disease. We hypothesize that an intervention designed to improve cellular function, like Juvenon Energy Formula, will have a beneficial effect on endothelial dysfunction in elderly patients with cardiovascular disease."

The Juvenon Energy Formula dietary supplement consists of two mitochondrial-activating components that improve energy levels, reduce signs of aging in revitalized cells and increase burning of fat for energy. This novel supplement was developed at the University of California, Berkeley by renowned scientist Bruce Ames, PhD, a winner of the National Medal of Science and other international honors, and Tory Hagen, PhD, a researcher at the Linus Pauling Institute at Oregon State University.

"We hope that the results from the trial will provide further validation of Juvenon Energy Formula's role in promoting cellular health," said Dr. Bruce Ames, a professor of molecular and cell biology at University of California, Berkeley and a researcher at Children's Hospital Oakland Research Institute (CHORI). "The finding that this supplement improves endothelial function would provide important new information about the role of the mitochondria in aging and cardiovascular disease."

This 40-person trial will determine the effect of Juvenon Energy Formula on the endothelial cells that line the blood vessels. The trial is designed to determine if an intervention to improve mitochondrial function (Juvenon Energy Formula) will have a beneficial effect on endothelial function. The study will test the blood vessels' ability to respond to changes in blood flow by dilating (expanding). Loss of normal dilator function reflects a loss of normal endothelial function and is associated with an increased risk of heart attack or stroke. The trial is designed as a double-blind, randomized, placebo-controlled crossover study and will enroll patients from 55 to 95 years old with proven coronary artery disease.

Juvenon Energy Formula™

The mitochondria, the power plants of the cell, are the weak link in aging. As we age, the efficiency of the mitochondria diminishes. Evidence has been accumulating that deterioration of mitochondria is an important cause of aging. The effects of aging—functional decline, degradation of physical appearance, and degenerative disease—are caused in large part by cumulative oxidative damage to mitochondria.

Juvenon Energy Formula™ facilitates the entry of fuel (starches and fatty acids) into mitochondria and stimulates production of natural antioxidants that protect the mitochondria and the cell from age-associated increases in tissue-damaging oxidants. It also restores the level of cardiolipin, an important structural element in the mitochondrial membrane.

In three articles in the 19 February 2002 issue of the Proceedings of the National Academy of Sciences, Ames and his colleagues reported results that showed that old laboratory rats, when given the ingredients in Juvenon Energy Formula, functioned at levels approaching those of much younger animals. The animals were more active and energetic and performed better on memory tests. All mitochondrial biochemical properties that were assayed were similar to those of young animals.

Each of the ingredients in the Juvenon Energy Formula has been individually proven safe in clinical studies conducted over the past 30 years. The product is currently being marketed as a dietary supplement. Juvenon is committed to maintaining an active research program and is presently conducting rigorous preclinical and clinical testing of its Juvenon Energy Formula, despite the fact that dietary supplements are not subject to FDA approval.

Juvenon, Inc. develops and sells products that promote cellular health and help maintain vigor and vitality during aging. Juvenon has an exclusive, worldwide license from the University of California, Berkeley for the technology of Drs. Ames and Hagen, and has received its own patents for certain cognitive effects and for increased energy and stamina. Juvenon plans to develop and launch both dietary supplements and nutritional products that focus on the mitochondria and the mechanics of the cellular engine.

Source

Juvenon, Inc. www.juvenon.com.